Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis.

MLA

Jones, Isabelle C., et al. “Targeting MAP3K19 Prevents Human Lung Myofibroblast Activation Both in Vitro and in a Humanized SCID Model of Idiopathic Pulmonary Fibrosis.” Scientific Reports, vol. 9, no. 1, Dec. 2019, p. 19796. EBSCOhost, https://doi.org/10.1038/s41598-019-56393-z.

APA

Jones, I. C., Espindola, M. S., Narayanan, R., Coelho, A. L., Habiel, D. M., Boehme, S. A., Ly, T. W., Bacon, K. B., & Hogaboam, C. M. (2019). Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis. Scientific Reports, 9(1), 19796. https://doi.org/10.1038/s41598-019-56393-z

Chicago

Jones, Isabelle C, Milena S Espindola, Rohan Narayanan, Ana L Coelho, David M Habiel, Stefen A Boehme, Tai Wei Ly, Kevin B Bacon, and Cory M Hogaboam. 2019. “Targeting MAP3K19 Prevents Human Lung Myofibroblast Activation Both in Vitro and in a Humanized SCID Model of Idiopathic Pulmonary Fibrosis.” Scientific Reports 9 (1): 19796. doi:10.1038/s41598-019-56393-z.